Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Seeking Alpha
Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera Therapeutics. Yes, I'm told that if you have questions, you want to ask in the audience, please scan the QR code and then you're able to ask a question, and then I will be able to pick it up here on the iPad and ask you questions. So please feel free to scan the QR code and then put your questions in there. All right. With that out of the way, it's our great pleasure to welcome Jared Gollob, Chief Medical Officer of Kymera. Jared, thank you for joining us. Jared Gollob Chief Medical Officer Yes. Thanks, David. Thanks for having me. Xiaochuan Dai UBS Investment Bank, Research Division That's great. Question-and-Answer Session Xiaochuan Dai UBS Investment Bank, Re
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025GlobeNewswire
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewswire
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- KYMR's page on the SEC website